Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study.
A randomized, double-blind comparison of lactose enemas plus placebo tablets vs. starch enemas plus neomycin tablets was performed on 18 patients with acute portal systemic encephalopathy. Ten patients received starch enemas (10%; 1000 ml t.i.d.) plus neomycin tablets and 8 patients received lactose enemas (20%; 1000 ml t.i.d.) plus placebo tablets. A significant mental state improvement was demonstrated in the group of patients treated with starch enemas-neomycin tablets (p less than 0.05) and in the group of patients treated with lactose enemas-placebo tablets (p less than 0.025). Both treatments significantly improved the frequency of asterixis, ammonia blood levels, and electroencephalograms. In addition, patients treated with lactose enemas showed significant improvement in number-connection test times (p less than 0.02), and their stools showed a more acid pH (p less than 0.05). No side effects were evident with either treatment. Lactose enemas are a safe and effective treatment for acute portal systemic encephalopathy.
D000208:Acute Disease; D000328:Adult; D004311:Double-Blind Method; D004733:Enema; D005243:Feces / Q000032:analysis; D005260:Female; D006501:Hepatic Encephalopathy / Q000628:therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007785:Lactose / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use*; D010919:Placebos; D011897:Random Allocation; D013213:Starch / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D013213:Starch; D009355:Neomycin; D007785:Lactose